Saturday 17 October 2026 Export HIND’s income statement to Excel — free account

Vyome Holdings, Inc.

In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.

1.87 0.04 −2.09%

Follow HIND

Alert me

Market cap: $13.4M
P/E: 0.0×
Fwd P/E: −3.1×
Dividend yield: —
F-score: 4/9
Altman Z: −22.00
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 52.84%

Capital & Financial Ratios $m

Market Cap 13.41

Revenue 0.13

Net Income (11.58)

Free Cash Flow (5.58)

Net Debt (7.89)

Current Ratio 4.37

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.06)

P/S ratio 101.12

P/B ratio 1.80

Past 5Y EPS Growth —

This Y EPS Growth 86.47%

Next Y EPS Growth (29.74%)

Next Y revenue growth (67.78%)

Next 5Y EPS Growth 45.10%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 38.30%

10-year low 10-year high

P/B against its own 10 years 37.71%

10-year low 10-year high

EV/Sales against its own 10 years 38.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	0	5	8
Receivables	2	1	—	—
Inventory	4	2	—	—
Other	—	0	0	0
	10	0	5	8

	2023	2024	2025	Q'26
Payables	2	1	1	1
ST’ Debt	—	4	—	—
Other	0	0	0	0
	4	6	3	2

Compound Annual Growth %

	10y	5y	3y
Sales	(22.40%)	(50.98%)	(69.47%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(23.64%)	0.91%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	2	2	0	—	0
’23	2	2	2	2	9
’22	2	3	3	3	11
’21	3	4	4	3	14
’20	1	2	4	5	11

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	0	0	(2)	(1)	(4)
’24	(2)	(1)	3	0	(1)
’23	(5)	(7)	(3)	(2)	(17)
’22	(7)	(6)	(5)	(3)	(22)
’21	(2)	(2)	(8)	(3)	(15)
’20	(5)	(1)	(1)	(2)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	0	0	(2)	(1)	(4)
’24	(2)	(1)	3	0	(1)
’23	(5)	(7)	(3)	(2)	(17)
’22	(7)	(6)	(5)	(3)	(22)
’21	(2)	(2)	(8)	(3)	(16)
’20	(5)	(1)	(1)	(2)	(9)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.15)	(0.10)	—	—	—
’25	(761.59)	(771.90)	(3.12)	1.53k	(4.86)
’24	(523.26)	(348.84)	(1.37k)	(189.00)	(6.01k)
’23	(9.07k)	(6.28k)	(5.93k)	10.15k	(11.10k)
’22	(127.91k)	(145.35k)	(151.16k)	(207.18k)	(633.14k)
’21	(1.24)	(0.86)	(1.04)	(723.84k)	(1.45m)
’20	(0.68)	(0.52)	(1.32)	(148.27k)	(5.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	71,949,000.00	56,845,800.00	12,702,000.00	1,322,400.00	539,400.00	466,900.00	31,320.00	1,078.80	409.00	3.35	Analyst estimates 2026–2028 Powerpack
	High	138,156,000.00	114,666,000.00	71,209,504.00	20,271,000.00	2,723,100.00	9,369,900.00	539,400.00	129,920.00	2,900.00	519.00
People
People	Employees	11	137	103	34	2	47	40	31	18	18
	Revenue/emp, $m	0.31	0.07	0.09	0.10	5.65	0.29	0.28	0.28	0.01	0.02
Income, $m
Income, $m	Revenue	3	10	9	3	11	14	11	9	0	0
	Gross margin, %	17.21	51.29	40.41	10.09	55.42	61.38	60.52	63.93	75.91	68.44
	EBT	(20)	(35)	(37)	(24)	(22)	(63)	(47)	(11)	(1)	(10)
	EBT margin, %	(603.21)	(350.67)	(410.72)	(721.61)	(193.03)	(466.32)	(414.54)	(130.62)	(563.45)	(3,277.35)
	Net income	(20)	(35)	(37)	(24)	(22)	(63)	(46)	(11)	(1)	(10)
	Depreciation	0	0	1	1	3	2	2	0	0	0
Per share, $
Per share, $	Revenue	0.80	0.59	4.78	0.70	2.89	0.00	112,400.00	8,678.00	1,284.50	0.15
	Earnings	(4.85)	(2.08)	(19.63)	(5.03)	(5.54)	(1,453,488.00)	(633,139.50)	(11,104.65)	(6,006.06)	(4.86)
	Cash flow	(4.59)	(1.83)	(15.46)	(4.86)	(2.19)	0.00	(219,020.00)	(16,960.00)	(3,070.50)	(1.73)
	Capex	(0.08)	(0.06)	(0.67)	(0.04)	(0.10)	0.00	(920.00)	(10.00)	1.50	0.00
	Free cash flow	(4.67)	(1.89)	(16.13)	(4.90)	(2.29)	0.00	(219,940.00)	(16,970.00)	(3,069.00)	(1.73)
	Book value	15.23	2.10	6.88	3.37	3.71	0.00	36,610.00	6,663.00	(21,955.00)	1.74
	Shares, m	4	17	2	5	4	0	0	0	0	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	99,162,871.79	104,890,153.82	3,767,622.90	2,371,432.79	451,015.58	0.00	0.81	0.18	0.35	23.25
	P/B	5,232,246.70	29,615,270.27	2,616,093.39	490,925.04	351,765.38	0.00	2.48	0.23	0.00	1.98
	EV/Sales	99,162,853.42	104,890,150.35	3,767,622.41	2,371,428.85	451,016.44	(0.98)	1.29	0.72	49.61	47.56
	EV/FCF	(17,061,843.90)	(32,838,000.14)	(1,116,400.72)	(337,409.28)	(570,026.26)	0.85	(0.66)	(0.37)	(20.76)	(4.06)
Cash, $m
Cash, $m	Operating cash flow	(19)	(31)	(29)	(23)	(9)	(15)	(22)	(17)	(1)	(4)
	Capex	0	(1)	(1)	0	0	0	0	0	0	—
	Free cash flow	(20)	(32)	(31)	(23)	(9)	(16)	(22)	(17)	(1)	(4)
Balance, $m
Balance, $m	Working capital	73	42	11	14	(3)	22	2	7	(5)	3
	Total debt	10	10	10	1	13	0	0	—	4	—
	Net debt	(66)	(34)	(14)	(13)	10	(23)	(4)	(5)	3	(5)
	Shareholders’ equity	64	35	13	16	14	44	4	7	(4)	4
Returns, %
Returns, %	ROA	(44.02)	(52.72)	(89.55)	(93.25)	(75.30)	(140.96)	(145.16)	(104.44)	(24.04)	(260.50)
	ROIC	0.00	(3,384.94)	0.00	(496.88)	(32.10)	(165.96)	0.00	(456.96)	0.00	0.00
	ROE	(446.59)	(69.94)	(155.04)	(163.53)	(142.60)	(214.71)	(192.58)	(220.59)	(127.42)	3,262.96

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 1 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLVSQ Clovis Oncology, Inc.	$14.2M	— (loss-making)	— (loss-making)	−19.13% (below 0%: shrinking)	n/m	+11.83% (above 0%: growing)	71.93%	(144.26%)	Compare
BCDA BioCardia, Inc.	$14.2M	— (loss-making)	— (loss-making)	−93.02% (below 0%: shrinking)	n/m	−5.15% (below 0%: shrinking)	100.00%	0.00%	Compare
RVLP RVL Pharmaceuticals PLC	$14.1M	— (loss-making)	— (loss-making)	−2.25% (below 0%: shrinking)	n/m	−734.24% (below 0%: shrinking)	76.43%	(266.66%)	Compare
LPCN Lipocine Inc.	$13.9M	— (loss-making)	— (loss-making)	−69.48% (below 0%: shrinking)	n/m	−60.56% (below 0%: shrinking)	100.00%	(1,495.11%)	Compare
KTTA Pasithea Therapeutics Corp.	$13.7M	— (loss-making)	— (loss-making)	+1,494.04% (above 0%: growing)	n/m	−21.68% (below 0%: shrinking)	0.00%	0.00%	Compare
ICU SeaStar Medical Holding Corporation	$13.5M	— (loss-making)	— (loss-making)	+81.95% (above 0%: growing)	n/m	+0.43% (above 0%: growing)	91.22%	(616.42%)	Compare
HIND Vyome Holdings, Inc.	$13.4M	0.0×	— (loss-making)	−46.00% (below 0%: shrinking)	n/m	−195.04% (below 0%: shrinking)	43.33%	(3,194.81%)
ALLR Allarity Therapeutics, Inc.	$13.2M	— (loss-making)	— (loss-making)	—	n/m	+53.22% (above 0%: growing)	100.00%	0.00%	Compare
CTXR Citius Pharmaceuticals, Inc.	$12.6M	— (loss-making)	—	—	n/m	−60.50% (below 0%: shrinking)	67.07%	(785.39%)	Compare
Median of peers	$13.8M	—	—	−10.69%	—	−13.41%	83.82%	(205.46%)

All 614 Biotechnology stocks →

Vyome Holdings, Inc. (HIND) key facts

Vyome Holdings, Inc. (HIND) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HIND traded at $1.87, a market capitalization of $13.4 million.
Return on equity was 3,263.0% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −22.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 1, 2026.